March 30, 2026 — Simcere Pharmaceutical Group Limited (2096.HK) announced that Phase III results from the RADIANT-AD study of rademikibart, an investi...

From March 13 to 16, 2026, the 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK. Data from a Phase I/II clin...

On March 16, 2026, Simcere Pharmaceutical Group (2096.HK) announced that the Phase 3 clinical trial of deuremidevir hydrobromide dry suspension (devel...

On February 2, 2026, Simcere Pharmaceutical Group (2096.HK) announced that its thrombolytic candidate drug for stroke, SIM0811, has recently initiated...